Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer's Disease Using Metabolomics

Eugenia Trushina, Tumpa Dutta, Xuan Mai T Persson, Michelle M. Mielke, Ronald C. Petersen

Research output: Contribution to journalArticle

Abstract

Alzheimer's Disease (AD) currently affects more than 5 million Americans, with numbers expected to grow dramatically as the population ages. The pathophysiological changes in AD patients begin decades before the onset of dementia, highlighting the urgent need for the development of early diagnostic methods. Compelling data demonstrate that increased levels of amyloid-beta compromise multiple cellular pathways; thus, the investigation of changes in various cellular networks is essential to advance our understanding of early disease mechanisms and to identify novel therapeutic targets. We applied a liquid chromatography/mass spectrometry-based non-targeted metabolomics approach to determine global metabolic changes in plasma and cerebrospinal fluid (CSF) from the same individuals with different AD severity. Metabolic profiling detected a total of significantly altered 342 plasma and 351 CSF metabolites, of which 22% were identified. Based on the changes of >150 metabolites, we found 23 altered canonical pathways in plasma and 20 in CSF in mild cognitive impairment (MCI) vs. cognitively normal (CN) individuals with a false discovery rate

Original languageEnglish (US)
Article numbere63644
JournalPLoS One
Volume8
Issue number5
DOIs
StatePublished - May 20 2013
Externally publishedYes

Fingerprint

Cerebrospinal fluid
Metabolomics
metabolomics
cerebrospinal fluid
Alzheimer disease
Metabolic Networks and Pathways
Cerebrospinal Fluid
biochemical pathways
Alzheimer Disease
Plasmas
Metabolites
metabolites
dementia
amyloid
Amyloid
Liquid Chromatography
diagnostic techniques
disease severity
liquid chromatography
Dementia

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer's Disease Using Metabolomics. / Trushina, Eugenia; Dutta, Tumpa; Persson, Xuan Mai T; Mielke, Michelle M.; Petersen, Ronald C.

In: PLoS One, Vol. 8, No. 5, e63644, 20.05.2013.

Research output: Contribution to journalArticle

Trushina, Eugenia ; Dutta, Tumpa ; Persson, Xuan Mai T ; Mielke, Michelle M. ; Petersen, Ronald C. / Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer's Disease Using Metabolomics. In: PLoS One. 2013 ; Vol. 8, No. 5.
@article{b32d3c60f327459bbc506666a4b46a04,
title = "Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer's Disease Using Metabolomics",
abstract = "Alzheimer's Disease (AD) currently affects more than 5 million Americans, with numbers expected to grow dramatically as the population ages. The pathophysiological changes in AD patients begin decades before the onset of dementia, highlighting the urgent need for the development of early diagnostic methods. Compelling data demonstrate that increased levels of amyloid-beta compromise multiple cellular pathways; thus, the investigation of changes in various cellular networks is essential to advance our understanding of early disease mechanisms and to identify novel therapeutic targets. We applied a liquid chromatography/mass spectrometry-based non-targeted metabolomics approach to determine global metabolic changes in plasma and cerebrospinal fluid (CSF) from the same individuals with different AD severity. Metabolic profiling detected a total of significantly altered 342 plasma and 351 CSF metabolites, of which 22{\%} were identified. Based on the changes of >150 metabolites, we found 23 altered canonical pathways in plasma and 20 in CSF in mild cognitive impairment (MCI) vs. cognitively normal (CN) individuals with a false discovery rate",
author = "Eugenia Trushina and Tumpa Dutta and Persson, {Xuan Mai T} and Mielke, {Michelle M.} and Petersen, {Ronald C.}",
year = "2013",
month = "5",
day = "20",
doi = "10.1371/journal.pone.0063644",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer's Disease Using Metabolomics

AU - Trushina, Eugenia

AU - Dutta, Tumpa

AU - Persson, Xuan Mai T

AU - Mielke, Michelle M.

AU - Petersen, Ronald C.

PY - 2013/5/20

Y1 - 2013/5/20

N2 - Alzheimer's Disease (AD) currently affects more than 5 million Americans, with numbers expected to grow dramatically as the population ages. The pathophysiological changes in AD patients begin decades before the onset of dementia, highlighting the urgent need for the development of early diagnostic methods. Compelling data demonstrate that increased levels of amyloid-beta compromise multiple cellular pathways; thus, the investigation of changes in various cellular networks is essential to advance our understanding of early disease mechanisms and to identify novel therapeutic targets. We applied a liquid chromatography/mass spectrometry-based non-targeted metabolomics approach to determine global metabolic changes in plasma and cerebrospinal fluid (CSF) from the same individuals with different AD severity. Metabolic profiling detected a total of significantly altered 342 plasma and 351 CSF metabolites, of which 22% were identified. Based on the changes of >150 metabolites, we found 23 altered canonical pathways in plasma and 20 in CSF in mild cognitive impairment (MCI) vs. cognitively normal (CN) individuals with a false discovery rate

AB - Alzheimer's Disease (AD) currently affects more than 5 million Americans, with numbers expected to grow dramatically as the population ages. The pathophysiological changes in AD patients begin decades before the onset of dementia, highlighting the urgent need for the development of early diagnostic methods. Compelling data demonstrate that increased levels of amyloid-beta compromise multiple cellular pathways; thus, the investigation of changes in various cellular networks is essential to advance our understanding of early disease mechanisms and to identify novel therapeutic targets. We applied a liquid chromatography/mass spectrometry-based non-targeted metabolomics approach to determine global metabolic changes in plasma and cerebrospinal fluid (CSF) from the same individuals with different AD severity. Metabolic profiling detected a total of significantly altered 342 plasma and 351 CSF metabolites, of which 22% were identified. Based on the changes of >150 metabolites, we found 23 altered canonical pathways in plasma and 20 in CSF in mild cognitive impairment (MCI) vs. cognitively normal (CN) individuals with a false discovery rate

UR - http://www.scopus.com/inward/record.url?scp=84877888815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877888815&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0063644

DO - 10.1371/journal.pone.0063644

M3 - Article

C2 - 23700429

AN - SCOPUS:84877888815

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e63644

ER -